Companies / Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc.

NYSE: PLXCIK 1006281HACKENSACK, NJ

Financials · FY2025

Revenue$52.74M
Net income$-6.60M
Total debt$912.0K
Cash$27.42M
Diluted EPS$-0.08
Shares outstanding80.6M

Ownership

80.6M shares outstanding · as of Aug 1, 2026
4.5%10%+ / strategic
Ownership
10%+ / strategic4.49%3,616,289
Institutions24.15%19,454,122
Public float71.37%57,501,231

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Mamlok GiladSr. VP and CFO
——

Institutional holders 92

View all →
HolderValue% of shares
BlackRock, Inc.$9.43M5.02%
Mak Capital One LLC$7.69M4.40%
Opaleye Management Inc.$4.46M3.08%
Renaissance Technologies LLC$2.66M1.52%
State Street Corporation$2.29M1.22%
Geode Capital Management, LLC$1.88M1.07%
Northern Trust Corp$1.56M1.07%
Stratos Wealth Partners, LTD.$900.0K0.62%
Vanguard Group Inc$879.4K0.61%
Citadel Advisors LLC$571.7K0.39%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
No activity matches these filters.

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
MAK Capital Fund LPPassive13G/A—3,616,289—
MAK Capital Fund LPPassive13G—4,649,599—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
PLX——74365A309—